Sökning: "NONMEM"

Visar resultat 1 - 5 av 46 avhandlingar innehållade ordet NONMEM.

  1. 1. Models for Ordered Categorical Pharmacodynamic Data

    Författare :Per-Henrik Zingmark; Mats O Karlsson; E. Niclas Jonsson; France Mentré; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Pharmacodynamic; Modelling; Categorical data; NONMEM; Proportional odds model; Markov model; Differential drug effect model; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI;

    Sammanfattning : In drug development clinical trials are designed to investigate whether a new treatment is safe and has the desired effect on the disease in the target patient population. Categorical endpoints, for example different ranking scales or grading of adverse events, are commonly used to measure effects in the trials. LÄS MER

  2. 2. Mechanism-Based Modeling of the Glucose-Insulin Regulation during Clinical Provocation Experiments

    Författare :Petra Jauslin-Stetina; Mats Karlsson; Nicolas Frey; Philippe Jacqmin; Uppsala universitet; []
    Nyckelord :Pharmacokinetics Pharmacotherapy; Glucose homeostasis; Type 2 diabetes; IVGTT; OGTT; Meal test; Circadian variation; Mechanism-based; NONMEM; Farmakokinetik Farmakoterapi;

    Sammanfattning : Type 2 diabetes is a complex chronic metabolic disorder characterized by hyperglycemia associated with a relative deficiency of insulin secretion and a reduced response of target tissues to insulin. Considerable efforts have been put into the development of models describing the glucose-insulin system. LÄS MER

  3. 3. Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials

    Författare :Kristin E Karlsson; E Niclas Jonsson; Mats O Karlsson; Anders Grahnén; Michael K Smith; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; model-based analysis; pharmacometrics; modeling; disease progression; NONMEM; SAEM; Importance sampling; repeated time-to-event; RTTCE; RCEpT; NIH stroke scale; Barthel index; internal validation; external validation; study power; study design; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Sammanfattning : Quantitative pharmacokinetic-pharmacodynamic and disease progression models are the core of the science of pharmacometrics which has been identified as one of the strategies that can make drug development more effective. To adequately develop and utilize these models one needs to carefully consider the nature of the data, choice of appropriate estimation methods, model evaluation strategies, and, most importantly, the intended use of the model. LÄS MER

  4. 4. Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel

    Författare :Anja Henningsson; Mats O. Karlsson; Lena Friberg; Iñaki F. Trocóniz; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacokinetics Pharmacotherapy; Pharmacokinetics; Pharmacodynamics; Mechanism-based; Modelling; Myelosuppression; Paclitaxel; Cremophor EL; NONMEM; Farmakokinetik Farmakoterapi; PHARMACY; FARMACI;

    Sammanfattning : Paclitaxel (Taxol®) is now widely used against breast, ovarian and non-small-cell lung cancer. Anticancer agents generally have narrow therapeutic indices, often with myelosuppression (mainly neutropenia) as dose-limiting side effect. LÄS MER

  5. 5. Applied Population Pharmacokinetic/ Pharmacodynamic Modeling of Antiretroviral and Antimalarial Drug Therapy

    Författare :Daniel Röshammar; Göteborgs universitet; Göteborgs universitet; Gothenburg University; []
    Nyckelord :HIV; malaria; pharmacokinetics; pharmacodynamics; pharmacometrics; NONMEM;

    Sammanfattning : HIV/AIDS and malaria are two major global infectious diseases. Although better drugs against these conditions are becoming more available, dosages may not always be optimal with respect to effectiveness, safety, cost or convenience of administration. LÄS MER